367 related articles for article (PubMed ID: 30621769)
1. EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy.
Kapp K; Volz B; Curran MA; Oswald D; Wittig B; Schmidt M
J Immunother Cancer; 2019 Jan; 7(1):5. PubMed ID: 30621769
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
4. Co-operation of α-galactosylceramide-loaded tumour cells and TLR9 agonists induce potent anti-tumour responses in a murine colon cancer model.
Dong T; Yi T; Yang M; Lin S; Li W; Xu X; Hu J; Jia L; Hong X; Niu W
Biochem J; 2016 Jan; 473(1):7-19. PubMed ID: 26450924
[TBL] [Abstract][Full Text] [Related]
5. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
Reilley MJ; Morrow B; Ager CR; Liu A; Hong DS; Curran MA
J Immunother Cancer; 2019 Nov; 7(1):323. PubMed ID: 31771649
[TBL] [Abstract][Full Text] [Related]
6. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
8. Empowering therapeutic antibodies with IFN-α for cancer immunotherapy.
Guo J; Xiao Y; Iyer R; Lu X; Lake M; Ladror U; Harlan J; Samanta T; Tomlinson M; Bukofzer G; Donawho C; Shoemaker A; Huang TH
PLoS One; 2019; 14(8):e0219829. PubMed ID: 31393905
[TBL] [Abstract][Full Text] [Related]
9. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
Kitahata Y; Kanuma T; Hayashi M; Kobayashi N; Ozasa K; Kusakabe T; Temizoz B; Kuroda E; Yamaue H; Coban C; Yamamoto T; Kobiyama K; Aoshi T; Ishii KJ
Oncotarget; 2016 Aug; 7(31):48860-48869. PubMed ID: 27384490
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist.
Sabree SA; Voigt AP; Blackwell SE; Vishwakarma A; Chimenti MS; Salem AK; Weiner GJ
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083419
[TBL] [Abstract][Full Text] [Related]
11. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
12. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.
Jacobs C; Duewell P; Heckelsmiller K; Wei J; Bauernfeind F; Ellermeier J; Kisser U; Bauer CA; Dauer M; Eigler A; Maraskovsky E; Endres S; Schnurr M
Int J Cancer; 2011 Feb; 128(4):897-907. PubMed ID: 20473889
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma.
Hajiabadi S; Alidadi S; Montakhab Farahi Z; Ghahramani Seno MM; Farzin H; Haghparast A
Front Immunol; 2023; 14():1258691. PubMed ID: 37901237
[TBL] [Abstract][Full Text] [Related]
14. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
15. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
[TBL] [Abstract][Full Text] [Related]
16. Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma.
Cascini C; Ratti C; Botti L; Parma B; Cancila V; Salvaggio A; Meazza C; Tripodo C; Colombo MP; Chiodoni C
J Exp Clin Cancer Res; 2023 Jun; 42(1):154. PubMed ID: 37365634
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation.
Temizoz B; Hioki K; Kobari S; Jounai N; Kusakabe T; Lee MSJ; Coban C; Kuroda E; Ishii KJ
Int Immunol; 2022 Jul; 34(7):353-364. PubMed ID: 35419609
[TBL] [Abstract][Full Text] [Related]
19. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
[TBL] [Abstract][Full Text] [Related]
20. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.
Yu D; Putta MR; Bhagat L; Dai M; Wang D; Trombino AF; Sullivan T; Kandimalla ER; Agrawal S
Antimicrob Agents Chemother; 2008 Dec; 52(12):4320-5. PubMed ID: 18852281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]